— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. — Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses. — For fiscal 2020, company expects revenues between $60 million and $65 million. […]
“— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. — Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses. — For fiscal 2020, company expects revenues between $60 million and $65 million. […]
· February 14, 2020
— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected.
— Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses.
— For fiscal 2020, company expects revenues between $60 million and $65 million. Operating expenses are projected to be between $165 million and $170 million.
— IMGN shares shot up 5.4% immediately following the announcement.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
